Win Advisors’s Biogen BIIB Stock Holding History

Win Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,686	Closed	-$1.02M	–	55
2024 Q4	$1.02M	Buy	+6,686	New	+$1.13M	0.49%	38

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Win Advisors's BIIB Position: Q1 2025 in Review

Win Advisors sold out of Biogen (BIIB) in Q1 2025, closing a stake of 6,686 shares — an estimated $1.02M sold.

Win Advisors first reported a position in BIIB in Q4 2024 and held it in 1 quarter. The position peaked at $1.02M in Q4 2024. 883 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

Win Advisors reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
Win Advisors sold 6,686 Biogen shares in Q1 2025, an estimated $1.02M.
Win Advisors first reported a position in Biogen in Q4 2024 and held it in 1 quarter.
Win Advisors's Biogen position peaked at $1.02M in Q4 2024.
883 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Win Advisors's 13F filing for Q1 2025, filed 23 Apr 2025.